Navigation Links
CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation
Date:1/4/2008

SAN DIEGO, Jan. 4 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today the publication of a European study of atrial fibrillation patients treated with CryoCor's Cardiac Cryoablation System. The purpose of the study was to evaluate the role of atrial flutter in the recurrence of atrial fibrillation and the effectiveness of an ablation strategy focused on isolating the pulmonary veins to treat the atrial fibrillation. The study was published in the December 11, 2007 issue of Circulation.

The 98-patient study was conducted by Dr. Wendel Moreira, Dr. Luz-Maria Rodriguez, Dr. Carl Timmermans and others in Academic Hospital Maastricht using CryoCor's Cardiac Cryoablation System. The study prospectively evaluated the best catheter ablation strategy in patients with paroxysmal atrial fibrillation with and without concomitant right atrial flutter. During follow-up averaging 26 months, the authors found that electrical isolation of the pulmonary veins by catheter ablation was successful in patients without concomitant atrial flutter at an 82% success rate. In patients with concomitant atrial flutter, the combination of ablation for atrial flutter and pulmonary vein isolation alone to treat atrial fibrillation was frequently insufficient in preventing recurrences of atrial fibrillation (recurrence rate of 67%). The authors concluded that those patients with atrial flutter and atrial fibrillation may require additional sites of ablation to effectively treat their atrial fibrillation.

Dr. Rodriguez, senior author of the study, stated, "This is the first time that an ablation strategy for paroxysmal atrial filbrillation and atrial flutter has been systematically studied. This has implications for the tools that a clinician may use to treat these atrial arrhythmias. Based on this study, we do not believe that it will be sufficient to simply isolate the pulmonary veins
'/>"/>

SOURCE CryoCor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. CryoCor Files Response to Patent Infringement Lawsuit
2. CryoCor Announces Web cast and Conference Call of Third Quarter 2007 Results
3. CryoCor Appoints New Vice President of Sales and Marketing
4. CryoCor to Present at Maxim Group First Annual Growth Conference in New York
5. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
6. FDA Reports New Risks Posed by Anemia Drugs
7. Lincare Holdings Inc. Reports Intention to File Shelf Registration Statement
8. UCI Medical Affiliates, Inc. Reports Fiscal Year End Results for September 30, 2007
9. The Ensign Group, Inc. Reports Third Quarter 2007 Earnings
10. HealthPartners Reports 2007 Most Cost Effective Programs Reduce Expenses by $74 Million
11. Par Pharmaceutical Reports Third-Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... “Have you recently been involved in an auto ... lawyer serving the greater Seattle area. “Are you still feeling ... keep reading . , In a recently released article, Dax ... accident can use to see if they may qualify for ... insurance claim will allow an individual to receive medical treatment ...
(Date:8/20/2014)... August 20, 2014 Low market concentration, ... availability of substitutes typify the market for packaging design ... 3.1 out of 5, indicating a moderate level of ... and suppliers have an equal amount of leverage during ... , First, few substitutes exist for packaging design ...
(Date:8/20/2014)... First Choice Emergency Room , the ... United States, named Richard Daniels, DO the Medical Director ... , “We are pleased to announce that Dr. Daniels ... facility in Pflugerville,” said Dr. James M. Muzzarelli, Executive ... Dr. Daniels received his undergraduate degree from Brigham Young ...
(Date:8/20/2014)... 2014 Kowa Optimed returns after a ... debut the new SL-17 portable slit lamp. , The ... LED source controlled by an illuminated thumb wheel for ... uses commercially available AAA rechargeable and dry cell batteries, ... requiring batteries designed specifically for the device. The new ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 This ... line of software defined networking, high availability cloud ... portfolio of Resellers, while allowing OPEN-V to sell ... is pleased to work with OPEN-V on this ... Donald Hows, manager distribution channels at storageFOUNDRY. "Nautilus ...
Breaking Medicine News(10 mins):Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 4Health News:First Choice Emergency Room Announces Dr. Richard Daniels as Medical Director of the Pflugerville – FM 685 Facility 2Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3
... 40 million Needy Children and Adults to be Affected Nationwide, Study ... ... A survey released today,by Spectrum Science Communications states that a little known,anti-privatization ... administer its Medicaid program. The,measure, offered as an amendment to the House-passed ...
... afflicted humans, primate ancestors , , FRIDAY, Feb. 29 (HealthDay News) ... as protection against a group of viruses that includes HIV ... that their finding suggests the current AIDS epidemic is not ... in Asian macaques is a hybrid of two existing proteins, ...
... Openings to Feature Cincinnati Reds Great, Doug Flynn, and Pitching ... ... RICHEY, Fla., Feb 29 Zounds,Hearing, a unique manufacturing and retail ... professional,service, opened its doors recently in the Westfield Sarasota Square Mall,(Sarasota) ...
... of Health Professionals Finds Acute Shortage of ... MILPITAS, Calif., Feb. 29 With mounting evidence that,many ... the,nation,s growing epidemic of diabetes, the Johnson & Johnson ... the U.S. to,improve how practitioners deliver diabetes care in ...
... lung cancer, according to a study of more than ... increase the risk of developing it. , Our study ... did not show any evidence for a decreased risk ... Slatore, M.D., of the University of Washington, in Seattle. ...
... diseases like chronic bronchitis, but genes also play a ... Sweden, who studied more than 40,000 Swedish twins to ... each play a role ion the development of chronic ... genetic component and smoking is a primary risk factor ...
Cached Medicine News:Health News:Farm Bill Provision Will Disrupt Arkansas Medicaid Program 2Health News:Farm Bill Provision Will Disrupt Arkansas Medicaid Program 3Health News:Monkey Gene That Blocks AIDS Viruses Evolved More Than Once 2Health News:Zounds! - Sarasota and Port Richey 'Hear' New Retail Concept Coming 2Health News:Zounds! - Sarasota and Port Richey 'Hear' New Retail Concept Coming 3Health News:Johnson & Johnson Diabetes Institute, LLC Launches New Center to Provide State-of-the-Art Education, Training to Health Professionals 2Health News:Johnson & Johnson Diabetes Institute, LLC Launches New Center to Provide State-of-the-Art Education, Training to Health Professionals 3Health News:Johnson & Johnson Diabetes Institute, LLC Launches New Center to Provide State-of-the-Art Education, Training to Health Professionals 4Health News:Johnson & Johnson Diabetes Institute, LLC Launches New Center to Provide State-of-the-Art Education, Training to Health Professionals 5Health News:Certain vitamin supplements may increase lung cancer risk, especially in smokers 2Health News:Genetic factors in smoking also increase risk of chronic bronchitis 2
(Date:8/19/2014)... Luoxis Diagnostics, Inc. , a ... MKT: AMPE), today announced an upcoming presentation at ... American Academy of Surgical Trauma (AAST) and Clinical ... Philadelphia, Pennsylvania that will be held ... from a recently completed five-year prospective clinical trial ...
(Date:8/19/2014)... , August 19, 2014 ,Weight ... Pipeline Assessment, 2014, report provides comprehensive insights about phase ... A key objective of the report is to establish ... III pipeline drugs across the different countries and regions. ... thoroughly, the report also provides details on the drug ...
(Date:8/18/2014)... Gamida Cell , a world ... today that it has signed an investment and option agreement ... Novartis " ) . According to the agreement, ... return will receive 15% equity and an option to fully ... period of time following achievement of certain milestones connected to ...
Breaking Medicine Technology:Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 2Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 3Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 4
... - Both co-primary endpoints, Wake After Sleep Onset and ... Sleep, were met at both doses - Evotec to ... 10am EST) today , HAMBURG, Germany | OXFORD, England, ... today positive top-line,results from its first phase II clinical ...
... Summary: Follow-up RAS data presented at ASCO , ... gave,a presentation titled "RAS peptide vaccination in resected,pancreatic ... long term survival" at ASCO's (American Society of ... of 23 resected pancreatic cancer patients,immunized in the ...
Cached Medicine Technology:Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 2Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 3Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 4Pharmexa A/S (DK) - Long lasting immune response and survival to,RAS vaccine 2
... MJS anatomic knee ... enhance durability, minimize polyethylene ... surfaces, to minimize contact ... and to achieve a ...
Simplified Design-Based on 15 Years of Experience...
... The result of more than a ... is based on a comprehensive study of ... resection, and tibial insert retrieval analysis.,As a ... axial rotation and motion patterns in total ...
... True to its leadership role within ... the clinical experience of the industry's leading ... Platform Knee System, with the clinically proven ... world's leading rotating platform knee. ,The result ...
Medicine Products: